Chongqing Lummy Pharmaceutical Co., Ltd. (300006.SZ)
CNY 5.25
(-2.42%)
CNY 5.25
(-2.42%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 895.59 Million | 884.58 Million | 1.22 Billion | 1.58 Billion | 1.85 Billion | 1.56 Billion |
| Cost of Revenue | 274.67 Million | 234.43 Million | 349.6 Million | 505.31 Million | 524.93 Million | 612.5 Million |
| Gross Profit | 620.91 Million | 650.14 Million | 875.62 Million | 1.07 Billion | 1.33 Billion | 949.85 Million |
| Operating Expenses | 564.68 Million | 705.68 Million | 922.69 Million | 1.1 Billion | 1.24 Billion | 787.75 Million |
| Selling, General and Administrative Expenses | 463.23 Million | 569.92 Million | 766.09 Million | 908.18 Million | 987.93 Million | 624.78 Million |
| Research and Development Expenses | 93.59 Million | 80.64 Million | 100.19 Million | 107.36 Million | 164.04 Million | 42.73 Million |
| Other Expenses | -4.86 Million | 20.79 Million | -35.82 Million | 2.48 Million | -786.09 Thousand | -196.14 Thousand |
| Cost and Expenses | 839.36 Million | 940.12 Million | 1.27 Billion | 1.6 Billion | 1.77 Billion | 1.4 Billion |
| Operating Income | -56.7 Million | -96.03 Million | -70.14 Million | -346.09 Million | -168.93 Million | 109.49 Million |
| Interest Expense | 12.59 Million | 20.34 Million | 32.07 Million | 83.18 Million | 72.33 Million | 57.87 Million |
| Income Tax Expense | 13.61 Million | 1.03 Million | -27.41 Thousand | 1.05 Million | -8.32 Million | 18.16 Million |
| Earnings before Tax | 3.59 Million | -75.24 Million | -105.96 Million | -343.6 Million | -169.71 Million | 109.3 Million |
| Net Income | -8.92 Million | -68.7 Million | -100.52 Million | -326.76 Million | -155.19 Million | 98 Million |
| Earnings Per Share Basic | -0.01 | -0.07 | -0.10 | -0.40 | -0.19 | 0.12 |
| Earnings Per Share Diluted | -0.01 | -0.07 | -0.10 | -0.40 | -0.19 | 0.12 |
| Weighted Average Shares Outstanding | 1.05 Billion | 1.05 Billion | 995.32 Million | 812.24 Million | 812.24 Million | 811.95 Million |
| Weighted Average Shares Outstanding (Diluted) | 1.05 Billion | 1.05 Billion | 995.32 Million | 812.24 Million | 812.24 Million | 811.95 Million |
| Gross Margin | 0.69 | 0.73 | 0.71 | 0.68 | 0.72 | 0.61 |
| EBIT Margin | 0.13 | 0.07 | 0.04 | 0.06 | 0.10 | 0.20 |
| Profit Margin | -0.01 | -0.08 | -0.08 | -0.21 | -0.08 | 0.06 |
| EBITDA | 116.49 Million | 19.47 Million | -1.19 Million | -148.57 Million | 34.51 Million | 281.57 Million |
| Earnings Before Tax Margin | -0.06 | -0.11 | -0.06 | -0.22 | -0.09 | 0.07 |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | 223.89 Million | 195.75 Million | 181.12 Million | 245.8 Million | 876.17 Million | 190.89 Million |
| Cost of Revenue | 88.41 Million | 74.39 Million | 63.72 Million | 86.36 Million | 314.31 Million | 61.85 Million |
| Gross Profit | 135.47 Million | 121.35 Million | 117.39 Million | 159.44 Million | 561.85 Million | 129.04 Million |
| Operating Expenses | 152.6 Million | 147.03 Million | 112.73 Million | 198.46 Million | 670.1 Million | 131.44 Million |
| Selling, General and Administrative Expenses | 189.78 Million | 131.41 Million | 118.19 Million | 152.72 Million | - | 172.58 Million |
| Research and Development Expenses | 18.46 Million | 15.3 Million | 10.29 Million | 44.39 Million | - | 20.03 Million |
| Other Expenses | -55.64 Million | -316.99 Thousand | -39.42 Thousand | -1.34 Million | -4.86 Million | -161.62 Thousand |
| Cost and Expenses | 241.02 Million | 221.43 Million | 176.46 Million | 284.82 Million | 984.42 Million | 193.29 Million |
| Operating Income | -27.43 Million | -25.68 Million | 1.8 Million | -39.01 Million | -108.25 Million | 1.65 Million |
| Interest Expense | 2.87 Million | 2.44 Million | 2.57 Million | 2.87 Million | 12.47 Million | 2.98 Million |
| Income Tax Expense | -3.06 Million | 6.15 Million | 1.73 Million | 14.64 Million | 13.61 Million | 2.4 Million |
| Earnings before Tax | -27.38 Million | 19.51 Million | 1.76 Million | 93.9 Million | 28.48 Million | 1.49 Million |
| Net Income | -27.74 Million | 5.9 Million | -4.57 Million | 45.58 Million | -8.92 Million | -456.92 Thousand |
| Earnings Per Share Basic | -0.03 | 0.01 | -0.00 | 0.04 | - | -0.00 |
| Earnings Per Share Diluted | -0.03 | 0.01 | -0.00 | 0.04 | - | -0.00 |
| Weighted Average Shares Outstanding | 1.05 Billion | 1.05 Billion | 1.06 Billion | 1.05 Billion | 1.05 Billion | 1.05 Billion |
| Weighted Average Shares Outstanding (Diluted) | 1.05 Billion | 1.05 Billion | 1.06 Billion | 1.05 Billion | 1.05 Billion | 1.05 Billion |
| Gross Margin | 0.61 | 0.62 | 0.65 | 0.65 | 0.64 | 0.68 |
| EBIT Margin | -0.11 | -0.06 | 0.04 | -0.08 | - | 0.04 |
| Profit Margin | -0.12 | 0.03 | -0.03 | 0.19 | -0.01 | -0.00 |
| EBITDA | -24.5 Million | -10.91 Million | 7.08 Million | -19.61 Million | - | 7.24 Million |
| Earnings Before Tax Margin | -0.12 | -0.13 | 0.01 | -0.16 | -0.12 | 0.01 |
6649
KINGSINFR
UAVS
7738
VMRI
002145